Deprenyl in Parkinson disease: personal experience

P. Giovannini, M. P. Grassi, G. Scigliano, I. Piccolo, P. Soliveri, T. Caraceni

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the therapeutic activity of Deprenyl in patients with Parkinson disease already being treated with L-Dopa+PDI. 15 selected patients were allocated to two groups according to clinical features and course of the disease, the first consisting of 9 patients with a mean disease duration of 5 years without any side-effects attributable to L-Dopa and the second of 6 patients with long-term illness (a mean disease duration of 8 years), side-effects and "on-off" phenomenon. All the patients of the first group completed the scheduled 10-week course of Deprenyl treatment obtaining a significant improvement on the baseline WRS scores, in tremor, in rigidity, in motility and a 30.5% reduction in the L-Dopa dose. The patients of the second group showed no significant modification of the symptoms; in 2 cases the treatment was discontinued due to acute delusional-hallucinatory disorders and deterioration of the involuntary movements. A more precise evaluation of Deprenyl activity in the L-Dopa syndrome will depend on further studies.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalItalian Journal of Neurological Sciences
Issue number2
Publication statusPublished - Jun 1985


  • L-Dopa long term treatment syndrome
  • L-Dopa+L-Deprenyl
  • Parkinson disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Deprenyl in Parkinson disease: personal experience'. Together they form a unique fingerprint.

Cite this